https://orcid.org/0000-0002-5433-0211
References
- Ball, P. (2021). The lightning-fast quest for COVID vaccines and what it means for other diseases. Nature, 589, 16–18.
- Davis, B.S., Chang, G.J., Cropp, B., Roehrig, J.T., Martin, D.A., Carl, D.A., Mitchell, J., Bowen, R. & Bunning, M.L. (2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a non-infectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. Journal of Virology, 75, 4040–4047.
- Entrican, G. & Francis, M.J. (2022). Applications of platform technologies in veterinary vaccinology and the benefits for One Health. Vaccine (forthcoming).
- Francis, M.J. (2017). Vaccination for One Health. International Journal of Vaccines and Vaccination, 4, 00090.
- Francis, M.J. (2018). Recent advances in vaccine technologies. Veterinary Clinics of North America: Small Animal Practice, 48, 231–241.
- Francis, M.J. (2020a). A veterinary vaccine process development map to assist in the development of new vaccines. Vaccine, 38, 4512–4515.
- Francis, M.J. (2020b). Understanding animal coronaviruses. The Biologist, 67, 20–21.
- Francis, M.J. (2021a). Spotlight on avian pathology: the importance of recombinant vector platform technologies in poultry vaccination. Avian Pathology, 50, 109–111.
- Francis, M.J. (2021b). Collaboration between human and veterinary medicine will be important in tackling any future pandemic disease threats. Science in Parliament, 77, 9–10.
- Joe, C.C.D., Jiang, J., Linke, T., Li, Y., Fedosyuk, S., Gupta, G., Berg, A., Segireddy, R.R., Mainwaring, D., Joshi, A., Cashen, P., Rees, B., Chopra, N., Nestola, P., Humphreys, J., Davies, S., Smith, N., Bruce, S., Verbart, D., Bormans, D., Knevelman, C., Woodyer, M., Davies, L., Cooper, L., Kapanidou, M., Bleckwenn, N., Pappas, D., Lambe, T., Smith, D.C., Green, C.M., Venkat, R., Ritchie, A.J., Gilbert, S.C., Turnerm, R. & Douglas, A.D. (2022). Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs. Biotechnology & Bioengineering, 119, 48–58.
- Joe, C.C.D., Segireddy, R.R., Oliveira, C., Berg, A., Li, Y., Doultsinos, D., Chopra, N., Scholze, S., Ahmad, A., Nestola, P., Niemann, J. & Douglas, A.D. (2022). Accelerating manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 days. bioRxiv, preprint. doi: https://doi.org/10.1101//2021.12,22.473478.
- Todd, J.I. (2007). Good manufacturing practice for immunological veterinary medicinal products. Revue Scientifique et Technique (International Office of Epizootics), 26, 135–145.
- Traxler, G.S., Anderson, E., LaPatra, S.E., Richard, J., Shewmaker, B. & Kurath, G. (1999). Naked DNA vaccination of Atlantic salmon Salmo salar against IHNV. Diseases of Aquatic Organisms, 30, 183–190.
- Warimwe, G.M., Francis, M.J., Bowden, T.A., Thumbi, S.M. & Charleston, B. (2021). Using cross-species vaccination approaches to counter emerging infectious diseases. Nature Reviews Immunology, 21, 815–822.